$ESPR
Esperion Therapeutics Inc Stock $espr

$espr Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024036762 Filed on August 12, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$51.63M	$73.83M
YoY Change	52.0%	186.33%
Cost Of Revenue	$17.29M	$15.61M
YoY Change	29.0%	130.02%
Gross Profit	$34.35M	$58.23M
YoY Change	66.73%	206.45%
Gross Profit Margin	66.52%	78.86%
Selling, General & Admin	$39.98M	$44.19M
YoY Change	20.26%	30.11%
% of Gross Profit	116.39%	75.89%
Research & Development	$10.40M	$11.46M
YoY Change	-30.15%	-48.14%
% of Gross Profit	30.27%	19.68%
Depreciation & Amortization	$26.00K	$10.00K
YoY Change	-13.33%	-80.39%
% of Gross Profit	0.08%	0.02%
Operating Expenses	$67.66M	$71.26M
YoY Change	10.01%	27.11%
Operating Profit	-$16.03M	$2.579M
YoY Change	-41.79%	-106.96%
Interest Expense	-$15.08M	-$11.32M
YoY Change	-200.58%	-21.57%
% of Operating Profit		-439.05%
Other Income/Expense, Net	$1.584M	$2.454M
YoY Change	23.94%	57.31%
Pretax Income	-$29.52M	-$61.93M
YoY Change	-28.51%	24.01%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$29.52M	-$61.93M
YoY Change	-28.43%	24.01%
Net Earnings / Revenue	-57.18%	-83.87%
Basic Earnings Per Share	-$0.15	-$0.33
Diluted Earnings Per Share	-$0.15	-$0.33
COMMON SHARES
Basic Shares Outstanding	196.2M shares	189.5M shares
Diluted Shares Outstanding	194.9M shares	188.8M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$144.7M	$189.3M
YoY Change	26.06%	36.71%
Cash & Equivalents	$144.7M	$189.3M
Short-Term Investments
Other Short-Term Assets	$14.91M	$10.98M
YoY Change	60.34%	52.86%
Inventory	$80.10M	$84.47M
Prepaid Expenses
Receivables	$67.82M	$60.36M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$307.6M	$345.1M
YoY Change	40.93%	48.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$281.0K	$307.0K
YoY Change	4583.33%	-87.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.559M	$7.211M
YoY Change	113.09%	188.32%
TOTAL ASSETS
Total Short-Term Assets	$307.6M	$345.1M
Total Long-Term Assets	$6.559M	$7.211M
Total Assets	$314.1M	$352.3M
YoY Change	41.94%	50.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$34.86M	$47.67M
YoY Change	33.0%	94.11%
Accrued Expenses	$77.54M	$74.24M
YoY Change	41.49%	67.98%
Deferred Revenue	$15.08M	$20.67M
YoY Change	-23.55%	32.22%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$165.9M	$175.3M
YoY Change	20.45%	63.6%
LONG-TERM LIABILITIES
Long-Term Debt	$262.9M	$262.5M
YoY Change	0.66%	0.67%
Other Long-Term Liabilities	$255.5M	$258.7M
YoY Change	9.95%	8.39%
Total Long-Term Liabilities	$518.5M	$521.2M
YoY Change	5.03%	4.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$165.9M	$175.3M
Total Long-Term Liabilities	$518.5M	$521.2M
Total Liabilities	$684.3M	$696.5M
YoY Change	8.4%	14.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.580B	-$1.550B
YoY Change	5.81%	6.78%
Common Stock	$195.0K	$195.0K
YoY Change	74.11%	93.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$370.2M	-$344.2M
YoY Change
Total Liabilities & Shareholders Equity	$314.1M	$352.3M
YoY Change	41.94%	50.16%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$29.52M	-$61.93M
YoY Change	-28.43%	24.01%
Depreciation, Depletion And Amortization	$26.00K	$10.00K
YoY Change	-13.33%	-80.39%
Cash From Operating Activities	-$35.32M	-$7.205M
YoY Change	82.84%	-70.89%
INVESTING ACTIVITIES
Capital Expenditures	$167.0K	$77.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$167.0K	-$77.00K
YoY Change		-100.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-9.095M	-30.02M
YoY Change	111.02%	-3811.12%
NET CHANGE
Cash From Operating Activities	-35.32M	-7.205M
Cash From Investing Activities	-167.0K	-77.00K
Cash From Financing Activities	-9.095M	-30.02M
Net Change In Cash	-44.59M	-37.31M
YoY Change	88.69%	479.18%
FREE CASH FLOW
Cash From Operating Activities	-$35.32M	-$7.205M
Capital Expenditures	$167.0K	$77.00K
Free Cash Flow	-$35.49M	-$7.282M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1728000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2005000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	65623000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86173000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1550187000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1549284000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-344220000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-454994000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	352319000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	205796000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	211569000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50115000	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	25684000	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	18438000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	24864000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	53480000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	63860000	usd
	us-gaap	Operating Expenses OperatingExpenses	136721000	usd
	us-gaap	Operating Expenses OperatingExpenses	135778000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	74848000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-85663000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	27747000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	28924000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-53235000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5231000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2933000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-903000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-111654000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.19
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109243845	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109243845	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179026191	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179026191	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	93927148	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93927148	shares
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-903000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-111652000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-323778000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	502000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2903000	usd
CY2023Q1	espr	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	52428000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-61719000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-329663000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3160000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4448000	usd
CY2023Q2	espr	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	10000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-49935000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-371978000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-454994000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3235000	usd
CY2024Q1	espr	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	90672000	usd
CY2024Q1	espr	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	5766000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	61022000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-294298000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2931000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2024Q2	espr	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	9042000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-61925000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-344220000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-903000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-111654000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-53235000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	espr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	7531000	usd
	espr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	0	usd
	us-gaap	Depreciation Depreciation	10000	usd
	us-gaap	Depreciation Depreciation	132000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	412000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	879000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	839000	usd
	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	21569000	usd
	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	22785000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6166000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6063000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11866000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7070000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6275000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3712000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4730000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	12127000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	18846000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10475000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15898000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1518000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-983000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	3329000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	46623000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-79106000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	42500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	150000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-150000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42500000	usd
	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	5832000	usd
	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	6616000	usd
	espr	Payments For Repurchase Of Revenue Interest Liability PaymentsForRepurchaseOfRevenueInterestLiability	343750000	usd
	espr	Payments For Repurchase Of Revenue Interest Liability PaymentsForRepurchaseOfRevenueInterestLiability	0	usd
	espr	Proceeds From Royalty Sale Liability Net Of Issuance Costs ProceedsFromRoyaltySaleLiabilityNetOfIssuanceCosts	304656000	usd
	espr	Proceeds From Royalty Sale Liability Net Of Issuance Costs ProceedsFromRoyaltySaleLiabilityNetOfIssuanceCosts	0	usd
	espr	Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockWarrantsAndPreFundedWarrantsNetOfIssuanceCosts	0	usd
	espr	Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockWarrantsAndPreFundedWarrantsNetOfIssuanceCosts	52428000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	90672000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	espr	Proceeds From Issuance Of Common Stock From Atm Program ProceedsFromIssuanceOfCommonStockFromATMProgram	0	usd
	espr	Proceeds From Issuance Of Common Stock From Atm Program ProceedsFromIssuanceOfCommonStockFromATMProgram	4479000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	14808000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	espr	Proceeds From Pre Funded Warrant Exercises ProceedsFromPreFundedWarrantExercises	0	usd
	espr	Proceeds From Pre Funded Warrant Exercises ProceedsFromPreFundedWarrantExercises	10000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60583000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50301000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	107056000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13695000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82248000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124775000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	189304000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138470000	usd
	espr	Common Stock Issuance Costs Incurred Not Yet Paid CommonStockIssuanceCostsIncurredNotYetPaid	0	usd
	espr	Common Stock Issuance Costs Incurred Not Yet Paid CommonStockIssuanceCostsIncurredNotYetPaid	31000	usd
	espr	Royalty Sale Issuance Costs Incurred But Not Yet Paid RoyaltySaleIssuanceCostsIncurredButNotYetPaid	9626000	usd
	espr	Royalty Sale Issuance Costs Incurred But Not Yet Paid RoyaltySaleIssuanceCostsIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	167000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	84000	usd
	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	36000	usd
CY2019Q3	espr	Estimated Number Of Study Patients EstimatedNumberOfStudyPatients	14000	patient
CY2024Q1	espr	Settlement Agreement Aggregate First Milestone Payment From Partner SettlementAgreementAggregateFirstMilestonePaymentFromPartner	100000000	usd
CY2024Q1	espr	Settlement Agreement Time Required To Pay Cash Portion Of Settlement SettlementAgreementTimeRequiredToPayCashPortionOfSettlement	P15D
CY2024Q1	espr	Settlement Agreement Aggregate Second Milestone Payment From Partner SettlementAgreementAggregateSecondMilestonePaymentFromPartner	25000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of June 30, 2024 and December 31, 2023, eleven customers accounted for all of the Company's net trade receivables. As of June 30, 2024 and December 31, 2023, three customers hold approximately 98% and 96% of the Company's trade receivables associated with net product sales, respectively. In the six months ended June 30, 2024 and 2023, three customers accounted for approximately 98% and 98% of gross sales of NEXLETOL and NEXLIZET, respectively.</span></div>
	espr	Number Of Sources Of Revenue NumberOfSourcesOfRevenue	2	revenue_source
CY2024Q1	espr	Settlement Agreement Aggregate First Milestone Payment From Partner SettlementAgreementAggregateFirstMilestonePaymentFromPartner	100000000	usd
CY2024Q1	espr	Settlement Agreement Time Required To Pay Cash Portion Of Settlement SettlementAgreementTimeRequiredToPayCashPortionOfSettlement	P15D
CY2024Q1	espr	Settlement Agreement Aggregate Second Milestone Payment From Partner SettlementAgreementAggregateSecondMilestonePaymentFromPartner	25000000	usd
CY2024Q1	espr	Settlement Agreement Aggregate First Milestone Payment From Partner SettlementAgreementAggregateFirstMilestonePaymentFromPartner	100000000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	76528000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	61890000	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4123000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3818000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	84469000	usd
CY2023Q2	espr	Potential Proceeds From Partner Milestone Payments PotentialProceedsFromPartnerMilestonePayments	300000000	usd
CY2024Q1	espr	Settlement Agreement Aggregate First Milestone Payment From Partner SettlementAgreementAggregateFirstMilestonePaymentFromPartner	100000000	usd
CY2024Q1	espr	Settlement Agreement Time Required To Pay Cash Portion Of Settlement SettlementAgreementTimeRequiredToPayCashPortionOfSettlement	P15D
CY2024Q1	espr	Settlement Agreement Aggregate Second Milestone Payment From Partner SettlementAgreementAggregateSecondMilestonePaymentFromPartner	25000000	usd
CY2024Q2	espr	Abbreviated New Drug Application Litigation Number Of Notices Received AbbreviatedNewDrugApplicationLitigationNumberOfNoticesReceived	9	company
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	143688000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	143688000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	68847000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	68847000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q2	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	usd
CY2024Q2	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
CY2023Q2	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
CY2022Q4	espr	One Time Partial Call OneTimePartialCall	50000000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-53200000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-53235000	usd
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	usd
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	usd
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	usd
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	usd
CY2020Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1994198	shares
	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	448698	shares
CY2024Q2	espr	Accrued Legal Fees Current AccruedLegalFeesCurrent	588000	usd
CY2023Q4	espr	Accrued Legal Fees Current AccruedLegalFeesCurrent	9202000	usd
CY2024Q2	espr	Accrued Deferred Finance Costs Current AccruedDeferredFinanceCostsCurrent	9626000	usd
CY2023Q4	espr	Accrued Deferred Finance Costs Current AccruedDeferredFinanceCostsCurrent	0	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7473000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10769000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4013000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2712000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	1325000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1325000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	269000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	990000	usd
CY2024Q2	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	23294000	usd
CY2023Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	24998000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3686191	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.88
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	584000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2082000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	100121	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	34.35
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1956	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.62
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5666114	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.19
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M2D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	569000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5666114	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.19
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M2D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	569000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2268300	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.89
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y5M23D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	185000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2900000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26071429	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	36344212	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	45944978	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	86332196	shares

Files In Submission

Name	View Source	Status
0001628280-24-036762-index-headers.html	Edgar Link	pending
0001628280-24-036762-index.html	Edgar Link	pending
0001628280-24-036762.txt	Edgar Link	pending
0001628280-24-036762-xbrl.zip	Edgar Link	pending
espr-20240630.htm	Edgar Link	pending
espr-20240630.xsd	Edgar Link	pending
espr-ex311x06302024.htm	Edgar Link	pending
espr-ex312x06302024.htm	Edgar Link	pending
espr-ex321x06302024.htm	Edgar Link	pending
exhibit101royaltysaleagree.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
espr-20240630_def.xml	Edgar Link	unprocessable
espr-20240630_lab.xml	Edgar Link	unprocessable
espr-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
espr-20240630_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
espr-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESPR
Esperion Therapeutics Inc Stock $espr

2024 Q3 Form 10-Q Financial Statement

#000162828024036762 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR Esperion Therapeutics Inc Stock $espr

2024 Q3 Form 10-Q Financial Statement

#000162828024036762 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR
Esperion Therapeutics Inc Stock $espr